Results 131 to 140 of about 6,393,089 (340)
Identifying prognostic targets in metastatic prostate cancer beyond AR
FEBS Open Bio, EarlyView.Genome‐wide functional screens combined with a large gene expression database and clinical outcomes can identify new therapeutic vulnerabilities in prostate cancer. Eight potentially druggable targets demonstrated strong dependency in cell lines, were associated with worse prognosis clinically, and showed evidence of protein expression in prostate ...
Emily Feng +13 more
wiley +1 more source
Web of Science Journal Citation Report 2020: the Brazilian contribution to the "Medicine, General & Internal" category of the journal impact factor (JIF) ranking (SCI 2019). [PDF]
Sao Paulo Med J, 2020 Atallah ÁN, Puga MEDS, Amaral JLGD.
europepmc +1 more source
Book Review: “Ultrasound for the Generalist: A Guide to Point-of- Care Imaging”
POCUS Journal, 2022 Daniel Restrepo
doaj +1 more source
Pain medicine: general view to the problem
Медицина болю, 2017 The explosive growth of our knowledge of every aspect of pain in recent years has produced major advances in the classification and management of the varieties of pain.
M. G. Tsagareli
doaj
The Results of a Year's Use of Vaccines in General Medicine [PDF]
, 1909 W. Hale White, J. W. H. Eyre
openalex +1 more source
Preparation and characterization of renal cell peptides from fetal rats for their antitumor activity
FEBS Open Bio, EarlyView.This study aimed to prepare renal cells (RCs) from fetal rats which were digested by enzymes. Candidate peptides RCPs were characterized by capillary HPLC and MS and their bioactivity was predicted using peptideranker. The predicted top 10 bioactive peptides were synthesized.
Zhe Zhang +6 more
wiley +1 more source
THE AMERICAN YEARBOOK OF MEDICINE AND SURGERY FOR 1902. VOL. I, GENERAL MEDICINE. [PDF]
, 1902 J. H. Long
openalex +1 more source
FEBS Open Bio, EarlyView.Phenotypic plasticity in a newly established set of EGFR inhibitor‐adapted NSCLC cell lines during adaptation and in established cell lines. Here, we introduce novel sublines of the EGFR‐mutant non‐small cell lung cancer (NSCLC) cell lines HCC827 and HCC4006 adapted to the EGFR kinase inhibitors gefitinib (HCC827rGEFI2μm, HCC4006rGEFI1μm), erlotinib ...
Tharsagini V. Nanthaprakash +6 more
wiley +1 more source